Written by [author]. Reviewed by [reviewer].
Updated . How we research and review.
Short answer
What is KLOW?
KLOW is a single lyophilised vial that holds four research compounds: BPC-157, TB-500, GHK-Cu and KPV. The amount of each compound in the vial is reported on its batch certificate.
Read the full explainer: what is KLOW?What is in each KLOW vial?
| STRENGTH | FORM | PRICE | CERTIFICATE |
|---|---|---|---|
| 80mg | Lyophilised powder | A$168 | Pending |
Which compounds are in KLOW?
| COMPOUND | CLASS | AUSTRALIA | WADA 2026 |
|---|---|---|---|
| BPC-157 | Synthetic 15-amino-acid peptide described as a fragment of a gastric juice protein (BPC) | Schedule 4 | S0 |
| TB-500 | Synthetic N-acetylated heptapeptide (Ac-LKKTETQ) matching residues 17-23 of mature thymosin beta-4 | Schedule 4 | S2.3 |
| GHK-Cu | Copper(II) complex of the endogenous tripeptide glycyl-L-histidyl-L-lysine (GHK) | Not named | Not named |
| KPV | Tripeptide (Lys-Pro-Val) matching the C-terminal residues 11-13 of alpha-melanocyte-stimulating hormone | Not named | Not named |
Does KLOW cost less than buying each compound?
The KLOW vial is A$168. The smallest vial of each component bought separately totals A$295. The amount of each compound in the blend is on its certificate [pending], so compare the price per milligram once it is published.
| BOUGHT SEPARATELY | STRENGTH | PRICE |
|---|---|---|
| BPC-157 | 5mg | A$81 |
| TB-500 | 10mg | A$98 |
| GHK-Cu | 50mg | A$58 |
| KPV | 10mg | A$58 |
| Total | A$295 | |
| KLOW vial | 80mg | A$168 |
What has research on KLOW examined?
No published study of the KLOW blend was found. The research below covers each component on its own.
BPC-157: Most published work on BPC-157 comes from rodent models and cell culture (for example tendon, gastrointestinal and vascular injury models), much of it from a single research group. Human data are limited to small uncontrolled pilot reports (e.g. a 2-participant intravenous safety pilot); a PubMed search found no records indexed as controlled clinical trials. TB-500: TB-500 has been examined mainly in analytical and anti-doping studies and in rodent and in vitro work (e.g. metabolite profiling in rats, rat Achilles tendon models). Controlled human trials identified on PubMed concern full-length thymosin beta-4 (a 43-residue protein, e.g. a phase I intravenous study in healthy volunteers and phase II wound and dry-eye trials). None tested the TB-500 fragment. GHK-Cu (copper tripeptide-1, prezatide copper): GHK was identified in human plasma in the 1970s-1980s as a copper-binding tripeptide, and its copper complex has been studied in cell culture, animal wound models and in vitro human skin penetration. Most published work is cell and animal research plus reviews; large controlled human trials were not found. KPV: KPV has been examined in cell culture (e.g. human keratinocytes, intestinal epithelial cells) and in mouse models of colitis, often with delivery systems such as nanoparticles or hydrogels. A PubMed search found no records indexed as clinical trials in humans.
What adverse events have studies of KLOW reported?
BPC-157: Human data are limited to two small uncontrolled pilot reports: intravenous infusion in 2 adults, and a single bladder-wall injection in 12 women with interstitial cystitis. Both reported no side effects or adverse events (PMID 40131143, 39325560). No controlled human trials were found. TB-500: No study of the TB-500 fragment (Ac-LKKTETQ) reporting adverse events in humans was found. Trials of full-length thymosin beta-4, a different 43-residue molecule, reported infrequent mild-to-moderate adverse events with IV dosing in 40 healthy volunteers (PMID 20536472) and no adverse events with 0.1% eye drops in dry eye (PMID 26056426). GHK-Cu (copper tripeptide-1, prezatide copper): We found no study abstract that reports adverse events for GHK-Cu. The human studies found are small topical skin-care studies whose abstracts give no adverse-event data. In cultured human skin cells (keratinocytes), GHK-Cu was not cytotoxic (PMID 27892491). A 2026 review says rigorous human safety data for such unapproved peptides are scarce (PMID 41966639). KPV: No study reporting adverse events for KPV was found. PubMed returned no human studies of KPV. Published KPV work is in cell culture and rodent colitis models, and the fetched abstracts do not report adverse events.
These findings describe the people or animals in each study. The sources list gives every PubMed record.
How do you reconstitute and store KLOW?
Store the sealed vial frozen (about -20 degrees Celsius), dry and away from light until it is reconstituted.
After reconstitution with a sterile solvent, keep the solution at 2 to 8 degrees Celsius and avoid repeated freezing and thawing. Record the solvent, volume and date on the vial label.
BAC Water is the usual laboratory solvent. Dilute acetic acid is an alternative for peptides that dissolve poorly in water. The reconstitution guide and storage guide cover laboratory handling.
| STATE | TEMPERATURE | NOTES |
|---|---|---|
| Sealed vial | -20 °C | Dry and dark. Keeps to the label date. |
| Reconstituted | 2 to 8 °C | Sterile technique. Avoid repeat freeze and thaw. |
| In transit | Cold pack | Refrigerate or freeze on arrival. |
Is KLOW legal to buy in Australia?
BPC-157 is listed in Schedule 4 of the Poisons Standard (prescription only). It is also listed in Appendix D clause 5, which makes possession without authority an offence. Source: the June 2026 Poisons Standard instrument (F2026L00633).
TB-500 has its own Schedule 4 entry in the Poisons Standard, and thymosin beta-4 has a separate one. Both are listed in Appendix D clause 5, which makes possession without authority an offence. Source: the June 2026 Poisons Standard instrument (F2026L00633).
GHK-Cu is not named in the Poisons Standard. Schedule 4 lists copper compounds for human use, with exceptions; whether a GHK-Cu product falls inside that entry has not been confirmed. Source: the June 2026 Poisons Standard instrument (F2026L00633).
KPV is not named in the Poisons Standard (June 2026 instrument). Source: the June 2026 Poisons Standard instrument (F2026L00633).
WADA's 2026 Prohibited List prohibits BPC-157 at all times, under class S0.
WADA's 2026 Prohibited List prohibits TB-500 at all times, under class S2.3.
GHK-Cu is not named on WADA's 2026 Prohibited List. WADA's S0 class covers any substance without government approval for human use, so Sport Integrity Australia is the body to confirm its status.
KPV is not named on WADA's 2026 Prohibited List. WADA's S0 class covers any substance without government approval for human use, so Sport Integrity Australia is the body to confirm its status.
Are peptides legal in Australia?How fast does KLOW ship?
Orders placed before [cut-off] leave Western Australia the same business day with tracking, by [carrier]. Delivery estimates for each state are on the shipping page.
KLOW questions
What has research on KLOW examined?
No published study of the KLOW blend was found. Research on each component: BPC-157: Most published work on BPC-157 comes from rodent models and cell culture (for example tendon, gastrointestinal and vascular injury models), much of it from a single research group. Human data are limited to small uncontrolled pilot reports (e.g. a 2-participant intravenous safety pilot); a PubMed search found no records indexed as controlled clinical trials. TB-500: TB-500 has been examined mainly in analytical and anti-doping studies and in rodent and in vitro work (e.g. metabolite profiling in rats, rat Achilles tendon models). Controlled human trials identified on PubMed concern full-length thymosin beta-4 (a 43-residue protein, e.g. a phase I intravenous study in healthy volunteers and phase II wound and dry-eye trials). None tested the TB-500 fragment. GHK-Cu (copper tripeptide-1, prezatide copper): GHK was identified in human plasma in the 1970s-1980s as a copper-binding tripeptide, and its copper complex has been studied in cell culture, animal wound models and in vitro human skin penetration. Most published work is cell and animal research plus reviews; large controlled human trials were not found. KPV: KPV has been examined in cell culture (e.g. human keratinocytes, intestinal epithelial cells) and in mouse models of colitis, often with delivery systems such as nanoparticles or hydrogels. A PubMed search found no records indexed as clinical trials in humans.
What adverse events have studies of KLOW reported?
BPC-157: Human data are limited to two small uncontrolled pilot reports: intravenous infusion in 2 adults, and a single bladder-wall injection in 12 women with interstitial cystitis. Both reported no side effects or adverse events (PMID 40131143, 39325560). No controlled human trials were found. TB-500: No study of the TB-500 fragment (Ac-LKKTETQ) reporting adverse events in humans was found. Trials of full-length thymosin beta-4, a different 43-residue molecule, reported infrequent mild-to-moderate adverse events with IV dosing in 40 healthy volunteers (PMID 20536472) and no adverse events with 0.1% eye drops in dry eye (PMID 26056426). GHK-Cu (copper tripeptide-1, prezatide copper): We found no study abstract that reports adverse events for GHK-Cu. The human studies found are small topical skin-care studies whose abstracts give no adverse-event data. In cultured human skin cells (keratinocytes), GHK-Cu was not cytotoxic (PMID 27892491). A 2026 review says rigorous human safety data for such unapproved peptides are scarce (PMID 41966639). KPV: No study reporting adverse events for KPV was found. PubMed returned no human studies of KPV. Published KPV work is in cell culture and rodent colitis models, and the fetched abstracts do not report adverse events.
Which compounds are in KLOW?
KLOW holds BPC-157, TB-500, GHK-Cu and KPV. The batch certificate reports the measured amount of each.
Does KLOW cost less than buying each compound?
The KLOW vial costs A$168. Buying the smallest vial of each component separately costs A$295. The amount of each compound in the blend is on its certificate [pending], so compare the price per milligram once it is published.
Is KLOW sold for human use?
No. KLOW is sold for laboratory research use only. It is not a medicine and is not for human or veterinary use.
Where is KLOW shipped from?
Orders ship tracked from Western Australia. Orders placed before [cut-off] leave the same business day. Delivery estimates by state are on the shipping page.
Is KLOW a prescription medicine in Australia?
BPC-157 is listed in Schedule 4 of the Poisons Standard (prescription only). It is also listed in Appendix D clause 5, which makes possession without authority an offence. TB-500 has its own Schedule 4 entry in the Poisons Standard, and thymosin beta-4 has a separate one. Both are listed in Appendix D clause 5, which makes possession without authority an offence. GHK-Cu is not named in the Poisons Standard. Schedule 4 lists copper compounds for human use, with exceptions; whether a GHK-Cu product falls inside that entry has not been confirmed. KPV is not named in the Poisons Standard (June 2026 instrument). Peptides Collective sells the blend for laboratory research use only.
Can I buy each compound in KLOW separately?
Yes. BPC-157 (from A$81), TB-500 (from A$98), GHK-Cu (from A$58), KPV (from A$58) are each sold on their own, with their own certificates.
How is KLOW reconstituted?
One reconstitution covers every compound in the vial. BAC Water is the usual laboratory solvent. Record the solvent, volume and date on the vial label.
How long does an unopened KLOW vial keep?
A sealed vial of lyophilised powder keeps to the date on its label when stored frozen, dry and dark. Once reconstituted, keep the solution at 2 to 8 degrees Celsius and record the date on the label.
Is KLOW tested as one batch?
Yes. The blended vial is tested as one batch. The certificate reports identity and content for every compound in the vial.
How do I match my vial to its certificate?
Find the batch number printed on the vial label, then search it in the certificate library. The result shows the lab, method, purity and test date for that batch.
Sources
- 1. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and tissue research, 2019. PMID 30915550.
- 2. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949.
- 3. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985), 2011. PMID 21030672.
- 4. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453.
- 5. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024. PMID 38382158.
- 6. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926.
- 7. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature, 1980. PMID 7453802.
- 8. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2011. PMID 20721598.
- 9. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative medicine and cellular longevity, 2012. PMID 22666519.
- 10. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. PMID 18061177.
- 11. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory bowel diseases, 2008. PMID 18092346.
- 12. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. The Journal of investigative dermatology, 2004. PMID 15102092.
- 13. Poisons Standard, June 2026 instrument (F2026L00633). Federal Register of Legislation.
- 14. World Anti-Doping Code, 2026 Prohibited List. WADA.
